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Human reaction to drugs, including chemotherapeutics,
is an extremely complex process, with many enzymes of
different metabolic and signal transduction pathways
involved. Despite the knowledge already gathered, the
exact mechanisms responsible for individual patients’
responses to chemotherapy drugs, including adverse
reactions, are still not clear. Cellular transport and
detoxification systems evolved as natural protection
against xeniobiotics and they process substrates that
belong to diverse chemical classes. There is evidence
that polymorphic variants in genes encoding proteins
involved in influx, efflux and two metabolism phases
(i.e. ABC and SLC transporters, CYP and GST enzymes
family) can both influence chemotherapeutic regimes’
effectiveness and toxicity. Also, because the drug-
induced damages to nucleic acid structure are responsi-
ble for activating cell death programme, it is assumed
that, apart from transport and detoxification systems,
resistance to these drugs can also be the result of effec-
tive DNA repair systems, defective checkpoint activation
and flawed recognition of DNA adducts. It is plausible
that functional polymorphisms in genes encoding key
proteins of said mechanisms (i.e. ERCC and XRCC
families, p53, ATM) will influence cells’ sensitivity to
drugs.
Chemotherapeutic regimes are usually composed of
non-crossing agents aimed at a variety of cellular targets
and processes in order to overcome cells’ resistance to
single drugs, for example 5-fluorouracil, doxorubicin
and cyclophosphamide are used as FAC regime in breast
cancer, or carbo/cisplatin administered with paclitaxel in
treatment of ovarian cancer. This approach substantially
increases the chance of success of a treatment, but also
increases the number of factors potentially responsible
for treatment failure and/or severe adverse reactions.
Consistently, insensitivity or oversensitivity to multidrug
treatment has to be a result of global changes in activity
of proteins involved in every, or some of the mechan-
isms responsible for used drugs transport, metabolism,
and their specific impact on the cell. For FAC, it has
been shown that pyrimidine analog 5-fluorouracil’s
effectiveness could be modulated in the presence of
polymorphic variants in SLC22, CYP, and GST gene
families. Similarly to 5-fluorouracil, polymorphisms in
genes for CYPs could be responsible for different cells’
reaction to cyclophosphamide, and reduced drug detoxi-
fication rates could be connected to functional variants
in GST isoform genes. For the ovarian cancer paclitaxel/
cisplatin regime there is strong evidence that accumula-
tion of several polymorphic variants is responsible for
elevated risk of death and progression (PGR, ATM and
ABCB1 gene variants). Such accumulation is also corre-
lated with many symptoms of chemotherapy systemic
toxicities, such as haematological - including neutrope-
nia, gastro-intestinal and hepatological toxicity (poly-
morphisms in ATP7B and PGR genes).
The search for genetic factors connected to the high risk
of treatment failure and severe toxicity has become one of
the foundations of personalised medicine. Simultaneous
analysis of many genetic factors, which individually may
have very subtle impact on the cellular processes and
therefore may be omitted, allows the understanding of
their cumulative impact on the chemotherapy response.
Insight into the complex molecular mechanisms resulting
in drug resistance or oversensitivity during cancer treat-
ment, may be potentially relevant for the further research
focused on developing drugs tailored to cancer patients’
genetic profile.
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